Exploring CX3CR1 as a prognostic biomarker and immunotherapeutic target in sarcoma.

ABSTRACT:

Background

Sarcomas (SARC) are a diverse group of malignant tumors originating from mesenchymal tissues, characterized by poor prognosis under conventional therapies. CX3CR1, a chemokine receptor involved in immune cell migration, has emerged as a key player in SARC. Post-translational modifications (PTMs) such as phosphorylation and ubiquitination critically modulate CX3CR1, influencing cancer progression, immune responses, and treatment resistance.

Methods

This study investigates CX3CR1 expression, its biological functions, and prognostic value in SARC. Using data from The Cancer Genome Atlas (TCGA), we analyzed CX3CR1 gene expression, methylation patterns, CRISPR screening results, and immune infiltration metrics. Functional experiments included knockout and overexpressio

SUBMITTER: Li T 

PROVIDER: S-EPMC11787715 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature